Uncategorized

Los resultados de un experimento de autoguiado y toma de decisiones sin participación humana por parte de una flotilla de pequeños satélites en órbita a la Tierra permiten vislumbrar un futuro en el que, para bien o para mal, habrá flotas de satélites inteli …

The company has begun a major marketing campaign to support the launch of its MiniMed Flex insulin pump.

Con la creciente preocupación por los efectos contaminantes del uso de combustibles fósiles de aviación, y el avance del calentamiento global como consecuencia de dicha fuente de contaminación atmosférica y las demás que provocan un efecto invernadero, exist …

Scammers are masquerading as MyChart to trick patients into providing personal information. Epic says that the increase in phishing attempts are just cybercriminals taking advantage of the MyChart brand rather than a security concern.

The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication. The new target action date for the therapy is November 22.

Sondermind and Limbic are evaluating digital health devices intended to help with anxiety and depression.

The two countries failed to reach an agreement before Saturday’s deadline for the Section 338 levies, with Canada vowing to “match those tariffs dollar for dollar.” 

The FDA has placed a clinical hold on RGX-121 after small nodules or cystic masses were detected in the spines of five patients enrolled in REGENXBIO’s registrational trial. The biotech no longer plans to resubmit the candidate—which was rejected in February—in the near term.

Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.

Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.